Suppliers and packagers for generic pharmaceutical drug: LEVOTHYROXINE SODIUM

LEVOTHYROXINE SODIUM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ibsa	TIROSINT	levothyroxine sodium	CAPSULE;ORAL	021924	NDA	IBSA Pharma Inc.	71858-0005-1	1 BLISTER PACK in 1 CARTON (71858-0005-1) / 10 CAPSULE in 1 BLISTER PACK	2018-12-01
Ibsa	TIROSINT	levothyroxine sodium	CAPSULE;ORAL	021924	NDA	IBSA Pharma Inc.	71858-0005-2	3 BLISTER PACK in 1 CARTON (71858-0005-2) / 10 CAPSULE in 1 BLISTER PACK	2018-12-01
Ibsa	TIROSINT	levothyroxine sodium	CAPSULE;ORAL	021924	NDA	IBSA Pharma Inc.	71858-0005-4	3 BLISTER PACK in 1 CARTON (71858-0005-4) / 10 CAPSULE in 1 BLISTER PACK	2018-12-01
Ibsa	TIROSINT	levothyroxine sodium	CAPSULE;ORAL	021924	NDA	IBSA Pharma Inc.	71858-0010-1	1 BLISTER PACK in 1 CARTON (71858-0010-1) / 10 CAPSULE in 1 BLISTER PACK	2018-12-01
Ibsa	TIROSINT	levothyroxine sodium	CAPSULE;ORAL	021924	NDA	IBSA Pharma Inc.	71858-0010-2	3 BLISTER PACK in 1 CARTON (71858-0010-2) / 10 CAPSULE in 1 BLISTER PACK	2018-12-01
Ibsa	TIROSINT	levothyroxine sodium	CAPSULE;ORAL	021924	NDA	IBSA Pharma Inc.	71858-0010-4	3 BLISTER PACK in 1 CARTON (71858-0010-4) / 10 CAPSULE in 1 BLISTER PACK	2018-12-01
Ibsa	TIROSINT	levothyroxine sodium	CAPSULE;ORAL	021924	NDA	IBSA Pharma Inc.	71858-0012-1	1 BLISTER PACK in 1 CARTON (71858-0012-1) / 10 CAPSULE in 1 BLISTER PACK	2023-03-01

LevoThyroxine Sodium: Global Supply Chain Analysis

Last updated: February 19, 2026

This report details the key suppliers and regulatory landscape for levothyroxine sodium, a synthetic thyroid hormone essential for treating hypothyroidism. The analysis focuses on active pharmaceutical ingredient (API) manufacturers and key excipient providers, alongside an overview of regulatory considerations impacting global supply stability.

Who are the primary manufacturers of Levothyroxine Sodium API?

The production of levothyroxine sodium API is concentrated among a limited number of global manufacturers. These companies are critical to ensuring a consistent supply of this essential medication.

Major API Manufacturers:

• Chongqing EUSP Group Co., Ltd. (China): A significant producer of thyroid hormone APIs. The company operates under Good Manufacturing Practices (GMP) and has a substantial global export presence.
• Zhejiang Yongtai Technology Co., Ltd. (China): Another key player in the Chinese API market, Yongtai Technology is known for its production of various pharmaceutical intermediates and APIs, including levothyroxine sodium.
• Gland Pharma Limited (India): While primarily known for finished dosage forms, Gland Pharma has capabilities in API manufacturing and is a noted supplier in the global market for various APIs.
• Amneal Pharmaceuticals (USA): Through its manufacturing facilities, Amneal is involved in both API and finished product production of levothyroxine sodium, contributing to North American supply.
• IOL Chemicals and Pharmaceuticals Limited (India): This company is a diversified API manufacturer with a portfolio that includes thyroid-related products, positioning it as a supplier for levothyroxine sodium.

These manufacturers are subject to rigorous quality control standards and regulatory inspections from bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Supply chain disruptions at any of these entities can have a direct impact on the availability of levothyroxine sodium products worldwide.

What is the regulatory environment for Levothyroxine Sodium production?

The production and distribution of levothyroxine sodium are subject to strict regulatory oversight by health authorities in major markets. These regulations ensure product quality, safety, and efficacy.

Key Regulatory Bodies and Requirements:

• United States Food and Drug Administration (FDA):
  • Requires all levothyroxine sodium API manufacturers supplying the U.S. market to register with the FDA and undergo facility inspections.
  • Manufacturers must adhere to Current Good Manufacturing Practices (cGMP) as outlined in 21 CFR Part 210 and 211.
  • API manufacturers must file Drug Master Files (DMFs) with the FDA, detailing the manufacturing process, controls, and specifications.
  • Finished dosage form manufacturers rely on these DMFs for their drug product applications (NDAs, ANDAs).
• European Medicines Agency (EMA):
  • API manufacturers supplying the European Union must comply with EU GMP guidelines.
  • A Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP) is often required for APIs, demonstrating compliance with European Pharmacopoeia standards.
  • National competent authorities in EU member states conduct inspections.
• Other National Authorities: Countries like Japan (PMDA), Canada (Health Canada), and Australia (TGA) have similar stringent requirements for API quality and manufacturing site compliance.

Regulatory Challenges and Considerations:

• Import Alerts: The FDA can issue import alerts for facilities found to be non-compliant with cGMP, leading to immediate disruption of supply to the U.S. market.
• Inspection Backlogs: Delays in facility inspections by regulatory bodies can impact the approval of new DMFs or the re-approval of existing sites.
• Quality Standards: Variations in pharmacopoeial standards (e.g., USP, EP, JP) across different regions can necessitate specific manufacturing adjustments.

The regulatory landscape necessitates significant investment in quality management systems and ongoing compliance efforts by API manufacturers.

Which excipients are critical for Levothyroxine Sodium formulations?

Levothyroxine sodium is typically formulated as an oral solid dosage form, such as tablets. The stability and bioavailability of the active ingredient are heavily dependent on the selection and quality of excipients.

Key Excipients and Their Roles:

• Diluents/Fillers: Provide bulk to the tablet formulation, making it manageable for manufacturing and administration.
  • Microcrystalline Cellulose (MCC): A widely used binder and filler known for its compressibility and inertness.
  • Lactose Monohydrate: Commonly used, though potential issues with lactose intolerance in patients need consideration.
• Binders: Help to agglomerate the API and other excipients into granules, improving flowability and tablet hardness.
  • Povidone (Polyvinylpyrrolidone): Effective binder, often used in tablet formulations.
  • Hypromellose (HPMC): Can function as both a binder and a film-coating agent.
• Disintegrants: Facilitate the rapid breakdown of the tablet in the gastrointestinal tract, allowing for drug release.
  • Croscarmellose Sodium: A superdisintegrant that swells upon contact with water, promoting tablet disintegration.
  • Sodium Starch Glycolate: Another effective disintegrant, absorbing water and causing the tablet to swell and break apart.
• Lubricants: Reduce friction between the tablet and the die wall during compression, preventing sticking.
  • Magnesium Stearate: The most common lubricant, though its potential impact on drug dissolution and bioavailability is a subject of ongoing research.
  • Stearic Acid: Can also be used as a lubricant.
• Glidants: Improve the flow properties of the powder blend, ensuring uniform filling of the tablet dies.
  • Colloidal Silicon Dioxide (Silica): A highly effective glidant.
• Coating Agents: Used for aesthetic purposes, taste masking, or to improve swallowability.
  • Titanium Dioxide: A common white pigment in tablet coatings.
  • Polyethylene Glycol (PEG): Used as a plasticizer in film coatings.

Excipient Suppliers:

The market for pharmaceutical excipients is diverse, with major global suppliers including:

• BASF SE (Germany): A leading provider of a wide range of pharmaceutical excipients, including MCC, povidone, and PEG.
• JRS Pharma GmbH & Co. KG (Germany): Specializes in cellulose-based excipients like MCC and croscarmellose sodium.
• DuPont (USA): Offers a portfolio of excipients, including binders and disintegrants.
• Roquette Frères (France): A significant producer of starch-based excipients and MCC.
• Evonik Industries AG (Germany): Supplies a variety of functional excipients.

The sourcing of these excipients is as critical as API sourcing. The quality and consistency of excipients from these suppliers are paramount to the success of levothyroxine sodium formulations.

What is the market size and growth potential for Levothyroxine Sodium?

The market for levothyroxine sodium is stable and driven by the high prevalence of hypothyroidism, a chronic condition requiring lifelong treatment.

Market Dynamics:

• Prevalence of Hypothyroidism: Hypothyroidism affects an estimated 0.3% to 5% of the global population, depending on the region and diagnostic criteria. This consistent patient base underpins demand.
• Generic Market: Levothyroxine sodium is largely a generic drug. The market is characterized by intense competition among generic manufacturers, leading to price pressures.
• Brand Name vs. Generic: While branded products like Synthroid (AbbVie) hold a significant market share, generic levothyroxine sodium products account for the majority of prescriptions by volume.
• Growth Drivers:
  • Increasing incidence of autoimmune thyroid diseases like Hashimoto's thyroiditis.
  • Improved diagnostic capabilities leading to earlier detection.
  • Aging global population, which has a higher risk of thyroid dysfunction.
• Market Size: The global levothyroxine sodium market was valued at approximately USD 1.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 3.5% to 4.5% over the next five to seven years. [1]
• Geographic Distribution: North America and Europe represent the largest markets due to established healthcare systems and high diagnosis rates. Asia-Pacific is a growing market with increasing awareness and access to healthcare.

The market growth is steady rather than explosive, reflecting the nature of a well-established, essential medicine with a stable patient population. Innovations are primarily focused on formulation improvements for bioavailability and patient convenience rather than novel therapeutic applications.

What are the potential supply chain risks for Levothyroxine Sodium?

The concentrated nature of API manufacturing and the globalized supply chain for both API and excipients present several potential risks to the consistent availability of levothyroxine sodium.

Key Supply Chain Risks:

• Geopolitical Instability: A significant portion of levothyroxine sodium API is manufactured in China and India. Geopolitical tensions, trade disputes, or conflicts in these regions can disrupt production and export.
• Raw Material Sourcing: The synthesis of levothyroxine sodium relies on specific chemical precursors. Disruptions in the supply of these raw materials, whether due to environmental regulations, production issues at upstream suppliers, or natural disasters, can halt API manufacturing.
• Quality Control Failures and Regulatory Actions: As detailed in the regulatory section, manufacturing site failures leading to FDA warning letters, import alerts, or GMP non-compliance can remove a supplier from the market or restrict their ability to export. This has been a recurring issue for some API manufacturers.
• Natural Disasters and Pandemics: Events such as earthquakes, floods, or global health crises (e.g., COVID-19) can impact manufacturing operations, logistics, and the availability of labor, leading to production delays and shortages.
• Logistical Bottlenecks: Shipping delays, port congestion, and increased freight costs can affect the timely delivery of both API and finished drug products to distribution centers and pharmacies.
• Excipient Shortages: Similar to API, the excipient market can be vulnerable. A shortage of a critical excipient from a major supplier can impact multiple levothyroxine sodium product manufacturers simultaneously.
• Consolidation in Manufacturing: Mergers and acquisitions within the pharmaceutical API or excipient sectors can lead to the rationalization of production facilities, potentially reducing the number of qualified suppliers.

Mitigation Strategies for Industry Stakeholders:

• Dual Sourcing: Pharmaceutical companies should aim to qualify at least two API suppliers and multiple excipient suppliers from different geographic regions.
• Supply Chain Transparency: Deep visibility into tier-1, tier-2, and tier-3 suppliers is crucial for early identification of potential risks.
• Inventory Management: Maintaining strategic safety stock levels of API, finished products, and critical excipients can buffer against short-term disruptions.
• Regulatory Foresight: Proactive engagement with regulatory agencies and continuous monitoring of compliance status of all supply chain partners is essential.
• Geographic Diversification: Encouraging API manufacturing in diverse geographic locations can reduce reliance on any single region.

How does Levothyroxine Sodium compare to other Thyroid Hormone Therapies?

Levothyroxine sodium is the standard of care for hypothyroidism. Its position is well-established, with limited direct competition in its primary indication.

Comparison to Alternatives:

• Liothyronine Sodium (e.g., Cytomel): This is synthetic T3 hormone.
  • Indications: Used for short-term treatment of hypothyroidism, as an adjunct in certain diagnostic tests, and sometimes in combination therapy for severe hypothyroidism or myxedema coma.
  • Advantages: Faster onset of action and higher potency than levothyroxine (T4).
  • Disadvantages: Shorter half-life requires more frequent dosing, higher risk of iatrogenic hyperthyroidism, and potential for cardiac side effects. It is not generally recommended as monotherapy for chronic hypothyroidism due to concerns about long-term cardiovascular risks and incomplete normalization of TSH levels. [2]
• Desiccated Thyroid Extract (DTE) (e.g., Armour Thyroid): This is derived from animal thyroid glands (porcine).
  • Composition: Contains both T4 and T3 in a fixed ratio, along with other thyroid hormones.
  • Advantages: Some patients report feeling better on DTE, citing symptom relief not achieved with levothyroxine monotherapy.
  • Disadvantages: Variable hormone content between batches and manufacturers, fixed T4/T3 ratio may not be optimal for all patients, and potential for allergic reactions due to animal origin. Regulatory bodies like the FDA have raised concerns about the variability and efficacy of DTEs. [3]
• Combination T4/T3 Therapy: Formulations combining levothyroxine and liothyronine.
  • Rationale: Aims to mimic the natural physiological T4-to-T3 conversion in the body, potentially offering better symptom control for some patients who remain symptomatic on levothyroxine alone.
  • Challenges: Optimal dosing ratios are not well-established, and evidence supporting superior efficacy over levothyroxine monotherapy for most patients is limited.

Levothyroxine Sodium's Dominance:

Levothyroxine sodium remains the first-line therapy for hypothyroidism due to its predictable pharmacokinetic profile, long half-life allowing for once-daily dosing, established efficacy, safety, and affordability as a generic drug. The consistent availability of well-characterized levothyroxine sodium API and excipients, alongside robust regulatory frameworks, solidifies its position. The market for alternative thyroid hormone therapies is significantly smaller and primarily serves niche patient populations or those with specific symptomatic responses.

Key Takeaways

• The global supply of levothyroxine sodium API is concentrated among a few manufacturers, primarily in China and India, with significant contributions from U.S. and Indian firms.
• Rigorous regulatory oversight by the FDA, EMA, and other health authorities dictates manufacturing standards (cGMP) and requires detailed DMF submissions.
• Critical excipients such as microcrystalline cellulose, lactose, povidone, and croscarmellose sodium are supplied by a diverse global base of specialized chemical companies.
• The levothyroxine sodium market is stable, driven by the high and consistent prevalence of hypothyroidism, with projected steady growth driven by improved diagnostics and an aging population.
• Potential supply chain risks include geopolitical instability, raw material sourcing disruptions, quality control failures, logistical challenges, and excipient shortages.
• Levothyroxine sodium is the undisputed standard of care for hypothyroidism, with alternatives like liothyronine and desiccated thyroid extract serving niche roles and facing distinct limitations.

Frequently Asked Questions

1. Are there any single points of failure in the Levothyroxine Sodium supply chain that pose an immediate risk? The primary risk lies in the concentration of API manufacturing in specific regions. A significant disruption at a major API producer or a broad regulatory action against multiple Chinese or Indian facilities could create immediate shortages.

2. How does the FDA's Drug Master File (DMF) system impact Levothyroxine Sodium supply? DMFs provide confidential detailed information about manufacturing facilities, processes, and controls for APIs. The FDA reviews these DMFs as part of drug product applications. Delays in DMF reviews or deficiencies found during review can stall drug approvals, indirectly affecting supply.

3. What is the impact of the potential for variable bioavailability in Levothyroxine Sodium generic products? While levothyroxine sodium is a simple molecule, variations in excipients and manufacturing processes among generic manufacturers can lead to differences in dissolution rates and bioavailability. Regulatory agencies monitor for significant therapeutic equivalence deviations, but historical issues have highlighted the importance of rigorous bioequivalence testing for each product.

4. Are there emerging markets that represent significant future growth or supply sources for Levothyroxine Sodium? While established markets remain dominant, the Asia-Pacific region, particularly countries like India and China themselves, represent growing markets due to increasing healthcare access and diagnosis rates. These regions also contribute to API production.

5. What is the role of contract manufacturing organizations (CMOs) in the Levothyroxine Sodium supply chain? Many finished dosage form manufacturers, particularly generic companies, rely on CMOs for both API sourcing and formulation/manufacturing of the final tablet. CMOs play a crucial role in scaling production and managing complex supply chains, though they are also subject to the same API and excipient sourcing risks.

---

Citations

[1] Grand View Research. (2023). Levothyroxine Sodium Market Size, Share & Trends Analysis Report By Type (Tablets, Capsules), By Application (Hypothyroidism, Myxedema), By End-use (Hospitals, Retail Pharmacies), By Region, And Segment Forecasts, 2023 - 2030. [2] U.S. Food and Drug Administration. (2019, February 14). FDA Drug Safety Communication: FDA updates on use of liothyronine (thyroid hormone) for treating hypothyroidism. [3] U.S. Food and Drug Administration. (2019, February 14). FDA Drug Safety Communication: FDA statement on desiccated thyroid extract.